Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry

Blood (2013) 122 (21): 2613.

https://doi.org/10.1182/blood.V122.21.2613.2613

Published: 2013

Journal Articles

The B7-H3 Protein In Acute Myeloid Leukemia

Thomas Guéry, MD, Christophe Roumier, MD, Céline Berthon, MD, PhD, Pascale Lepelley, MD, Aline Renneville, MD, PhD, Olivier Nibourel, Florent Dumezy, MD, Valérie Soenen, MD, PhD, Catherine Roche, PhD, Claude Preudhomme, MD, PhD, Bruno Quesnel, MD, PhD

Blood (2013) 122 (21): 2620.

https://doi.org/10.1182/blood.V122.21.2620.2620

Published: 2013

Journal Articles

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Marie Sebert, Elodie Lainey, PAscale Lepelley, Sylvain Thepot, Maximilien Tailler, Claude Gardin, MD, Guido Kroemer, MD, PhD, Simone Boehrer, Lionel Ades, Pierre Fenaux, MD, PhD

Blood (2011) 118 (21): 5028.

https://doi.org/10.1182/blood.V118.21.5028.5028

Published: 2011

Journal Articles

Wilms' Tumor 1 (WT1) Gene Mutations in Pediatric T-Acute Lymphoblastic Leukemia.

Aline Renneville, Sophie Kaltenbach, Emmanuelle Clappier, Sandra Collette, Jean-Baptiste Micol, Brigitte Nelken, Pascale Lepelley, Nicole Dastugue, Yves Benoit, Yves Bertrand, MD, Claude Preudhomme, Hélène Cavé

Blood (2009) 114 (22): 3075.

https://doi.org/10.1182/blood.V114.22.3075.3075

Published: 2009

Journal Articles

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Blood (2008) 111 (2): 574–582.

https://doi.org/10.1182/blood-2007-06-096370

Published: 2008

Includes: Supplemental data

Journal Articles

Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.

Charikleia Kelaidi, MD, Sophie Park, MD, Sabine Brechignac, MD, Lionel Mannone, MD, Norbert Vey, MD, Herve Dombret, MD, Lina Aljassem, MD, Aspasia Stamatoullas, MD, Lionel Adès, MD, Stéphane Giraudier, MD, Stéphane de Botton, MD, Béatrice Mahé, MD, Pascale Lepelley, MD, Françoise Picard, MD, Geneviève Leroux, MD, Marie-Thérèse Daniel, MD, Didier Bouscary, MD, François Dreyfus, MD, Pierre Fenaux, MD

Blood (2006) 108 (11): 2678.

https://doi.org/10.1182/blood.V108.11.2678.2678

Published: 2006

Journal Articles

NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

Thorsten Braun, Gabrielle Carvalho, Arnaud Coquelle, Marie-Catherine Vozenin, Pascale Lepelley, François Hirsch, Jean-Jacques Kiladjian, Vincent Ribrag, Pierre Fenaux, Guido Kroemer

Blood (2006) 107 (3): 1156–1165.

https://doi.org/10.1182/blood-2005-05-1989

Published: 2006

Journal Articles

Impact of Traumatic Lumbar Puncture on CNS Relapse in Children with Acute Lymphoblastic Leukemia.

Charline Normand, MD, Estelle Thébaud-Léculée, MD, Francoise Mazingue, MD, Anne Lambilliotte, MD, Pascale Lepelley, MD, Brigitte Nelken, MD, Jean-Hugues Dalle, MD, PhD

Blood (2005) 106 (11): 879.

https://doi.org/10.1182/blood.V106.11.879.879

Published: 2005

Journal Articles

M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)

Blood (2003) 101 (4): 1277–1283.

https://doi.org/10.1182/blood-2002-05-1474

Published: 2003

Journal Articles

Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?

Charlotte Lamandin, Christophe Sagot, Christophe Roumier, Pascale Lepelley, Stéphane De Botton, Alain Cosson, Pierre Fenaux, Claude Preudhomme

Blood (2002) 100 (13): 4680.

https://doi.org/10.1182/blood-2002-08-2563

Published: 2002

Journal Articles

Unlike AML1, CBFβ gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes

Hugues Leroy, Christophe Roumier, Nathalie Grardel-Duflos, Elizabeth Macintyre, Pascale Lepelley, Pierre Fenaux, Claude Preudhomme

Blood (2002) 99 (10): 3848–3850.

https://doi.org/10.1182/blood.V99.10.3848

Published: 2002

NARROW

Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry

The B7-H3 Protein In Acute Myeloid Leukemia

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Wilms' Tumor 1 (WT1) Gene Mutations in Pediatric T-Acute Lymphoblastic Leukemia.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.

NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

Impact of Traumatic Lumbar Puncture on CNS Relapse in Children with Acute Lymphoblastic Leukemia.

M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)

Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?

Unlike AML1, CBFβ gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only